<DOC>
	<DOCNO>NCT01735084</DOCNO>
	<brief_summary>HYPOTHESES : 1 . That infants receive PHiD-CV10 booster 13 month age , compare control PHiD-CV10 booster ( i.e . standard PCV13 ) , high HiD antibody level , low carriage NTHi , less tympanic membrane perforation 18 36 month age . 2 . That infants receive PCV13 booster 13 month age , compare control PCV13 ( i.e . PHiD-CV10 booster ) high antibody level serotypes 3 , 6A 19A , less carriage serotypes , less tympanic membrane perforation 18 36 month age .</brief_summary>
	<brief_title>Using Pneumococcal Vaccines Combination Maximum Protection From Ear Lung Infections First 3 Years Life</brief_title>
	<detailed_description>BACKGROUND : PCV13 recommend PCV Australia , 3+0 non-Indigenous child 3+1 Indigenous child Western Australia , Queensland Northern Territory . The decision recommend PCV13 PHiD-CV10 primarily drive increase case invasive pneumococcal disease due serotype 19A ( 1 ) . However NT , last 3 year one case serotype 3 , 6A 19A invasive pneumococcal disease ( IPD ) per year Indigenous child less 2 year age . By contrast , almost 20 % young Indigenous child perforate tympanic membrane 60 % associate NTHi , compare 3 % serotypes 3 , 6A 19A . The PREV-IX_COMBO trial randomise control trial ( RCT ) two pneumococcal conjugate vaccine currently license Australia . Participating Indigenous infant live remote community 4 region NT randomise 28 38 day age allocate one three group : PHiD-CV10 2 , 4 , 6 month PCV13 2,4,6 month , investigational group 4-dose combination schedule PHiD-CV10 1,2 , 4 month plus PCV13 6 month . PREV-IX_BOOST build PREV-IX_COMBO address question answerable booster trial general population : The 7 month visit final assessment include PREV-IX_COMBO trial . In October 2011 standard PCV schedule Indigenous baby NT switch PHiD-CV10 PCV13 2 , 4 , 6 18 month age . Thus , baby PREV-IX_COMBO go receive PCV13 18 month age part standard care . An alternative innovative option take opportunity answer question : PCV13 PHiD-CV10 vaccine booster vaccine infant three PREV-IX_COMBO group , age booster give ? Secondary question : By randomise three different primary course group booster dose either PHiD-CV10 PCV13 , number secondary question propose . Outputs include comparative benefit ( immune carriage correlate ) schedule 3+1 PCV13 , 3+1 PHiD-CV10 , mixed vaccine schedule single dose PCV13 single dose PHiD-CV10 booster follow alternate vaccine primary course , booster option follow early mixed 4-dose primary course . Furthermore design allow evaluation 18 month age , 13 month boost versus boost specific vaccine component unique vaccine . For example , comparison booster effect HiD ( PHiD-CV10 ) HiD boost ( PCV13 ) antibody concentration nasopharyngeal carriage 18 month . By combine group possible compare subtle difference difference immunogenicity serotypes share two vaccine ( 1,4,5,6B,7F,9V,14,18C,19F,23F ) different carrier protein thus anticipate difference immunogenicity . PCVs NT : PCV7 , PHiD-CV10 ( Synflorix ) PCV13 ( Prevenar13 ) : Prevention invasive pneumococcal disease ( IPD ) primary goal pneumococcal conjugate vaccination infant . Effectiveness overall IPD generally remain high although IPD cause non-PCV7 type increase high risk group region , particularly associate serotypes 19A , 6A , 33F . These increase describe 'replacement phenomenon ' . In addition ongoing outbreak IPD due non-PCV7 type ; NT WA serotypes 1 12F account resurgence IPD case otherwise low risk group . Effectiveness PCVs all-cause pneumonia otitis medium greatly compromise replacement serotypes broad diversity non-pneumococcal respiratory bacterial pathogen continue cause high rate disease , non-typeable H. influenzae ( NTHi ) . Replacement serotypes , particularly 19A ( 2,3 ) NTHi , target new generation vaccine . In Australia two new PCVs license : 10-valent pneumococcal-Haemophilus influenzae protein-D conjugate vaccine , PHiD-CV10 ( Synflorix , GSK ) 13-valent PCV , PCV13 ( Prevenar13 , Pfizer ) . The two vaccine 10 pneumococcal serotypes common ( 1,4,5,6B,7F,9V,14,18C,19F,23F ) , however conjugate different carrier protein immune correlate indicate potential vaccine difference efficacy individual serotypes . PHiD-CV10 protein D NTHi carrier serotypes PCV13 non-toxic diphtheria protein ( CRM197 ) -conjugated , precursor PCV7 , three additional serotypes ( 3 , 6A 19A ) HiD . There efficacy trial directly compare vaccine ; licensure base immune correlate protection comparison PCV7 . Evidence HiD efficacy come single RCT otitis medium primary outcome . In trial original formulation ( PHiD-CV11 ) ~55 % efficacy vaccine type AOM , 35 % efficacy NTHi AOM follow 3+1 schedule . ( 3 ) This trial also demonstrate 43 % ( 95 % Confidence Interval ( CI ) : -17 72 , n ) reduction carriage vaccine serotypes 43 % ( 95 % CI : 1-67 ) reduction carriage H. influenzae . This finding replicate later trial , partially due low baseline rate NTHi carriage ( &lt; 10 % ) thus low power achieve statistical significance . The PREV-IX_COMBO trial therefore important providing data immunological correlate carriage different PHiD-CV10 schedule . However , extend follow-up comparison booster dose ( PREV-IX_BOOST proposal ) provide evidence inclusion PHiD-CV10 booster ( compare NT standard PCV13 18 month ) . In NT , booster pneumococcal vaccine recommend 18 month age . This largely due previous schedule include 23-valent pneumococcal polysaccharide vaccine ( 23PPV ) booster dose 18 month . A 3+1 PHiD-CV10 schedule replace 3+1 PCV7-23PPV 2009 , booster age remain 18 month . In Queensland ( QLD ) Western Australia ( WA ) vaccination schedule allow PCV13 boost 12 month age high risk Indigenous child . At present 4 intra-muscular immunization ( IMIs ) 12 month age Indigenous infant Northern Territory childhood vaccination schedule . Administration PCV booster 13 month age trial . The advantage clearly acceptability avoid fifth IMI 12 month . The disadvantage acceptability additional visit , inability ass concomitant administration . A combined booster dose vaccine ( e.g . Menitorix ) become available Australia course BOOST study . This would reduce number IMIs 12 month age potentially provide 'space ' PCV 12 month . Whilst data BOOST trial booster PCV dose 13 month ideal , data important useful answer primary question regard vaccine , Synflorix Prevenar13 best PCV booster vaccine Indigenous child . Surveillance otitis medium remote community show high rate disease week birth throughout early childhood , particularly tympanic membrane perforation second year life , thus support need booster dose . Between 2008 2010 , PCV7-vaccinated child , mean age tympanic membrane perforation 18 month ; child AOM perforation ( AOMwiP ) , mean age 13 month chronic suppurative OM ( CSOM ) 21 month . IPD case occur Indigenous non-Indigenous child less 2 year age serotypes ; 2009 7 case ; 2011 8 case . The majority IPD case child 2 year occur 12 18 month . In summary , precedent 12 month PCV booster Indigenous child WA QLD , high incidence IPD OM first half second year life support decision choose 13 month booster study . The mixed schedule still allow u compare boost versus boost HiD , 3,6A 19A . Antibody decay post-primary PCV7 pre-booster : Furthermore , publish data ( 4 ) PCV7 era show post-primary antibody level mean age 15 month ( range 0.32 0.83 microg/mL serotype 14 ) decline almost detect cord blood ( range 0.3647 1.1797 microg/mL ) . The clinical implication decay term memory response duration protection mucosal infection , pneumonia otitis medium , know , however vaccine efficacy lower mucosal compare invasive infection ( 5 ) . Which vaccine booster dose ? Mucosal disease ( OM respiratory illness ) : Culture ear discharge perforation show 60 % specimen AOMwiP culture NTHi 26 % cultured pneumococcus . For CSOM , figure 47 % 23 % respectively . Serotyping identify 19A 6A 20 % pneumococcal isolates , translate 5 % AOMwip 4 % CSOM specimens . NTHi also associate exacerbation chronic suppurative lung disease ( CSLD ) , bronchiectasis , young Indigenous child . ( 6 ) Percentage ear discharge specimen OM pathogens pneumococcus ( Spn ) , 19A , NTHi , M. catarrhalis neither Spn NTHi . Evidence efficacy single dose PHiD-CV10 boost &amp; inclusion Australian PCV13 3+0 schedule : A single dose PHiD-CV10 might valuable many Australian child receive 3+0 PCV13 schedule , provide immune protection NTHi . Group 2 PREV-IX_COMBO trial receive either PCV13 2,4,6 month randomise study PCV13 ( 4th dose ) PHiD-CV10 ( 1st dose ) 12 month age . Vesikari et al . ( 7 ) evaluate single dose PHiD-CV catch-up ( booster ) 2 5 year old child . Following 1 dose 2 5 year group ELISA pneumococcal response low reference group ( reference group : 3 primary dos booster 12 15 month ) several serotypes . Responses follow 1 dose child 2 5 year age suggest 2 dos may preferable . Unfortunately , HiD Geometric Mean Concentrations ( GMCs ) report . A trial underway Queensland evaluate double dose PHiD-CV10 preventing exacerbation CSLD old child . The BOOST trial non-CSLD child complement data . Invasive disease due PCV13 serotypes 3 , 6A 19A : In 2009 , 89 case IPD NT population , 59 2010 114 2011 ; 25 ( 10 % ) 262 case unique PCV13 serotypes ( 3 , 6A 19A ) 17 ( 7 % ) Indigenous , four ( 1.5 % ) Aboriginal child &lt; 2 year age - one per year ( unpublished , Centre Disease Control , NT Health ) . Episodes AOM respiratory illness 3 year age : A high rate clinic presentation occurs baby young child remote community . Our antibiotic trial prevention OM randomise infant mean age 5 month ( 9,10 ) record episode illness placebo active group approximately 6 month ( unpublished ) . Around 9 episode primary respiratory illness AOM ( 8.2 + 0.8 ) record note per child year second 6 month life . There publish data illness second third year life population . Whilst BOOST study unlikely sufficiently power detect group difference rate illness , measure report .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Australian Indigenous infant participant PREVIX_COMBO trial primary course pneumococcal conjugate vaccine , age least 2 month post final dose primary course . Signed informed consent . adverse reaction Prevenar13 Synflorix</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>randomize control trial</keyword>
	<keyword>pneumococcal conjugate vaccine</keyword>
	<keyword>booster dose</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>nasopharyngeal carriage</keyword>
	<keyword>Australian Indigenous</keyword>
	<keyword>pediatric</keyword>
</DOC>